ARC Stockton Arts Centre

email box.office@arconline.co.uk
box office 01642 525199

You are here

Cafe Scientifique: Which drugs, at what price and for whom?

Which drugs, at what price and for whom?

Dr. Karl Claxton
Health Economist                           
York University

Does the pressure to approve new drugs more quickly at prices that are too high disadvantage other areas of the NHS? How much can the NHS afford to pay for new drugs? When should we say no and accept that some effective drugs will not be available to NHS patients? These are difficult but unavoidable decisions. Economic analysis allows decisions to be made in an accountable and ethical way by asking whether the improvement in health outcomes they offer exceeds the improvement in health that would have been possible if the resources required had, instead, been made available for other health care activities that would benefit other NHS patients. The increasing pressure to approve new drugs more quickly at prices that are too high will only increase the harm done to NHS patients overall.

Karl Claxton is a Professor in the Department of Economics and the Centre for Health Economics at the University of York. He researches methods for the evaluation of health care technologies. He has worked with NICE and many government departments and also is engaged in decisions in global health, for example with the Bill and Melinda Gates Foundation (BMFG).


Tue 21 Mar

8pm

Today's Price:
Suggested donation £4

Led by: 
Dr. Karl Claxton